Skip to main content
. Author manuscript; available in PMC: 2017 Sep 5.
Published in final edited form as: Leuk Res. 2014 Sep 10;38(11):1332–1341. doi: 10.1016/j.leukres.2014.09.001

Figure 4. SGI-110 treatment induces hypomethylation and expression of NY-ESO-1 and MAGE-A3/A6 in U937 xenografts treated using a twice weekly x 3 week schedule.

Figure 4

SGI-110 at varying doses (6.1,12.2, 24.4mg/kg) or DAC (2.5mg/kg) administered twice weekly for three weeks (days 1, 4, 8, 11, 15, 18); and tumors were harvested. A) LINE-1 and NY-ESO-1 promoter methylation by bisulfite pyrosequencing; MAGE-A3/6 by MSP (Representative of two experiments). B) NY-ESO-1 and MAGE-A3/6 mRNA by qRT-PCR. C) NY-ESO-1 and MAGE-A protein expression by western blotting. Data represent 3 animals/group. *p<0.05 vs. vehicle; **p<0.05 vs. DAC.